Cannabis firm Curaleaf Q3 revenue slightly beats expectations

Curaleaf Holdings

05/11/2025 21:12

Overview

Curaleaf Q3 revenue of $320 mln slightly beats analyst expectations

Company's international revenue grows 56% yr/yr, driving overall growth

Adjusted gross margin improves to 50%, up 115 basis points yr/yr

Outlook

Curaleaf sees positive momentum despite macroeconomic pressures

Company aims to enhance product quality and expand margins

Curaleaf plans to leverage Dark Heart genetics for renewed growth

Result Drivers

INTERNATIONAL GROWTH - International revenue grew 56% yr/yr, significantly contributing to overall growth

DOMESTIC STABILITY - Domestic segment remained stable with modest growth despite price compression challenges

STRATEGIC INITIATIVES - Return to Our Roots plan enhances product quality and expands margins

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$320 mln
$316.82 mln (8 Analysts)
Q3 Adjusted EBITDA
$69 mln
Q3 Gross Profit
$159.70 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Curaleaf Holdings Inc is C$4.13, about 8.8% above its November 4 closing price of C$3.76

Press Release: ID:nCNWy3v5va

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)